Korean biotech firm purchased by Parataxis for Bitcoin treasury usage

INSUBCONTINENT EXCLUSIVE:
Parataxis Holdings, an affiliate of digital asset-focused investment company Parataxis Capital Management, is set to launch a Bitcoin-native
treasury platform in the South Korean public market.The firm announced on Friday it had entered a definitive agreement to invest 25 billion
South Korean won ($18.5 million) into Bridge Biotherapeutics, a publicly traded biotech company
Following the acquisition, Parataxis will take a controlling interest in the firm, which will be renamed Parataxis Korea and repurposed as a
Partner at Parataxis Capital
access to Bitcoin while emphasizing sound corporate governance and disciplined capital management
2025
after the New York-headquartered firm announced plans to go public through a $200 million special acquisition company, Cointelegraph
reported on June 10.The Parataxis announcement comes amid a wave of corporate Bitcoin adoption
More than 237 public companies now hold Bitcoin on their balance sheets, up from 124 firms just weeks earlier, representing roughly 3.96% of
the total BTC supply, according to BitcoinTreasuries.NET.Source: BitcoinTreasuries.NETRelated: Nasdaq-listed Mercurity Fintech to raise
to TradingView data
Bridge Biotherapeutics stock price, 1-day chart
develops therapeutics for the treatment of ulcerative colitis, fibrotic diseases and cancer.Earlier today, London-based artificial
intelligence solutions firm Pri0r1ty Intelligence Group announced plans to adopt Bitcoin as a reserve asset and payment solution without
disclosing a direct Bitcoin investment.Pri0r1ty Intelligence Group (GBX) stock, 1-day chart
of 32%, Google Finance data shows.Not all companies are benefiting equally
GameStop shares fell more than 22% after the video game retailer increased its convertible note offering to $2.25 billion, which some